{"product_id":"orasure-business-model-canvas","title":"OraSure Technologies Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure Technologies: Clear Business Model Canvas for Diagnostic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind OraSure Technologies's business model with a concise Business Model Canvas-showing how the company delivers value through point-of-care and over-the-counter diagnostics, specimen collection, and stabilization products; how it serves key testing and research markets; and how it drives revenue across products and channels for a clearer view of its commercial strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure partners with BARDA and the CDC to secure R\u0026amp;D funding-BARDA awarded $22.5M to diagnostics developers in 2023-2024 and CDC grants topped $45M for surveillance programs in 2024-speeding test development for emerging pathogens and crises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure relies on strategic distribution partners such as McKesson and Cardinal Health to access over 80,000 clinical sites; in 2024 these distributors handled roughly 60-70% of OraSure's diagnostic kit shipments, providing global logistics and cold-chain capacity that helped sustain a net revenue of $224.6M in 2024 for its point-of-care and collection device lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and private labs drive OraSure's molecular collection and stabilization tech; in 2024 over 120 academic trials used OraSure kits, supporting $18.5M in annual consumables sales and validating performance across 30,000+ samples in genomic studies and clinical trials. These partnerships frequently reveal new uses for existing collection hardware, spawning 5 patent filings tied to novel specimen applications in 2023-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure sells over-the-counter tests through retail chains like CVS and Walgreens and online platforms, reaching consumers directly for at-home HIV and respiratory virus screening; in 2024 retail accounted for ~45% of OraSure's consumer test revenue, boosting visibility and point-of-sale access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCVS\/Walgreens distribution: national footprint, thousands of stores\u003c\/li\u003e\n\u003cli\u003eOnline marketplaces: expand reach, 24\/7 sales\u003c\/li\u003e\n\u003cli\u003e2024 consumer test revenue share ≈45%\u003c\/li\u003e\n\u003cli\u003eAt-home testing demand rose ~18% YoY in 2023-24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Assay Developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure partners with biotech firms that OEM its specimen-collection and nucleic-acid stabilization tech into diagnostic platforms, extending use into oncology and microbiome R\u0026amp;D; OEM deals drove ~18% of product revenue in FY2024 ($20.7M of $115M total revenue).\u003c\/p\u003e\n\u003cp\u003eBy supplying as a component vendor, OraSure embeds its devices across workflows, increasing platform stickiness and recurring OEM orders-24% CAGR in OEM shipments 2019-2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOEM partnerships expand markets: oncology, microbiome\u003c\/li\u003e\n\u003cli\u003eFY2024 OEM revenue: $20.7M (18% of revenue)\u003c\/li\u003e\n\u003cli\u003eOEM shipment CAGR 2019-2024: 24%\u003c\/li\u003e\n\u003cli\u003eRole: component supplier → higher platform integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships drive rapid growth: BARDA\/CDC funding, distributors, OEMs, retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships: BARDA\/CDC funding ($22.5M BARDA, $45M+ CDC 2023-24) speeds R\u0026amp;D; McKesson\/Cardinal handle ~60-70% diagnostic shipments, supporting $224.6M point-of-care\/device revenue 2024; OEMs drove $20.7M (18% FY2024) with 24% OEM shipment CAGR 2019-2024; retail (CVS\/Walgreens) ~45% consumer test revenue 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA\/CDC\u003c\/td\u003e\n\u003ctd\u003e$22.5M \/ $45M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e60-70% shipments; $224.6M rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEMs\u003c\/td\u003e\n\u003ctd\u003e$20.7M (18%); 24% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e~45% consumer revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for OraSure Technologies detailing nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting real-world diagnostics and specimen-collection operations for investor and strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact one-page Business Model Canvas for OraSure Technologies that highlights how its diagnostic and specimen-collection solutions relieve pain points in point-of-care testing, enabling faster decisions, streamlined workflows, and reduced lab bottlenecks for clinicians and public-health programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure's R\u0026amp;D drives competitive advantage through continual molecular-chemistry and diagnostic-hardware innovation, targeting higher sensitivity\/specificity and simpler user flow for lay users; R\u0026amp;D spend was $25.4M in FY2024 (22% of revenue) as teams updated assays to detect new variants and meet evolving FDA EUA\/510(k) standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure navigates FDA approvals and global certifications continuously, spending ~12-18 months per assay and supporting \u0026gt;$30m in clinical studies since 2020 to meet regulatory benchmarks.\u003c\/p\u003e\n\u003cp\u003eThe firm enforces strict quality control-CAP\/ISO standards, routine GMP audits, and detailed clinical documentation-to sustain diagnostic safety and a device complaint rate under 0.5% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies runs high-throughput production lines in Bethlehem, PA and Boca Raton, FL that produced over 45 million diagnostic devices and specimen collection kits in 2024; strict QC processes and ISO 13485 compliance keep defect rates below 0.2%, preserving clinician and FDA trust, while supply-chain initiatives-dual sourcing and 12-week safety stock-cut raw-material disruption risk and reduced lead-time variability by 35% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSales and marketing prioritize active engagement with clinicians and procurement officers to drive adoption of OraSure's non-invasive, rapid diagnostics; in 2024 OraSure reported $160.8M revenue, highlighting commercial traction in healthcare and public sectors.\u003c\/p\u003e\n\u003cp\u003eThe team educates on accuracy and speed vs. lab tests while locking multi-year contracts with health systems and public health departments to stabilize recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage HCPs and procurement to drive adoption\u003c\/li\u003e\n\u003cli\u003eMarket education: benefits of non-invasive, rapid tests\u003c\/li\u003e\n\u003cli\u003eTarget: multi-year contracts with systems and health depts\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $160.8M (commercial traction)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProviding comprehensive training and support ensures OraSure Technologies' diagnostic devices are used correctly, reducing user error and improving result accuracy; in 2024 customer support cases citing user error fell 18% after expanded education programs.\u003c\/p\u003e\n\u003cp\u003eMaterials target clinical staff and at-home consumers; high-quality support boosts brand loyalty and lowers returns-OraSure reported a 12% rise in repeat orders and a 9% decline in product returns in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced user error: -18% support cases (2024)\u003c\/li\u003e\n\u003cli\u003eRepeat orders: +12% (2024)\u003c\/li\u003e\n\u003cli\u003eProduct returns: -9% (2024)\u003c\/li\u003e\n\u003cli\u003eAudiences: clinical staff and at-home consumers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure: Robust R\u0026amp;D, low-defect manufacturing, $160.8M revenue and improving customer metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's key activities: R\u0026amp;D ($25.4M, FY2024) updating assays for variants and FDA EUA\/510(k); regulatory \u0026amp; clinical studies (~12-18 months per assay; \u0026gt;$30M since 2020); manufacturing (45M devices\/kits in 2024; defect \u0026lt;0.2%); sales\/contracts (2024 revenue $160.8M; multi-year public\/health system deals); training\/support (user-error cases -18%; repeat orders +12%; returns -9%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$25.4M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/Clinical\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30M studies since 2020; 12-18 mo\/assay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e45M units (2024); defect \u0026lt;0.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\/Sales\u003c\/td\u003e\n\u003ctd\u003e$160.8M (2024); multi‑yr contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\/Training\u003c\/td\u003e\n\u003ctd\u003eUser errors -18%; repeat +12%; returns -9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic OraSure Technologies Business Model Canvas-not a mockup or sample-and it matches exactly the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this identical, fully formatted Business Model Canvas ready for editing, presenting, and sharing in the provided formats.\u003c\/p\u003e\n\u003cp\u003eNo surprises or omissions: the previewed content is a direct excerpt of the final deliverable, and purchasing unlocks the complete document instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies holds over 200 issued patents and pending filings on oral-fluid diagnostics and molecular stabilization (2025 portfolio), creating a strong barrier to entry and supporting recurring revenue from its HIV, HCV, and drug-testing lines; patent maintenance and legal defense consumed roughly $6-8M annually in 2024, a core expense to preserve $120M in reported product revenues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies owns and runs ISO 13485-compliant production plants with precision diagnostic lines; in 2024 these facilities produced \u0026gt;10 million test units and cut COGS by ~8% versus outsourced runs.\u003c\/p\u003e\n\u003cp\u003eFacilities scale rapidly-capacity surged 3x during 2020‑21 spikes-and internal manufacturing improved yield and quality control, lowering defect rates to \u0026lt;0.5% and stabilizing gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Technical Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheir workforce of ~220 scientists and engineers (2024 headcount) anchors OraSure's innovation pipeline, with molecular biologists and engineers ensuring technical integrity across diagnostics; R\u0026amp;D spend was $42.3M in FY2024, showing investment to retain top-tier talent. Retention is crucial: industry turnover above 15% raises product delays risk, so maintaining sub-10% turnover preserves market leadership in niche diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Reputation and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure's decades in infectious disease diagnostics, with 2024 revenue of $198.5M and core oral-fluid HIV\/epidemiology market share \u0026gt;30%, gives it proven brand trust that speeds regulatory approvals and buyer confidence.\u003c\/p\u003e\n\u003cp\u003eThat trust helped secure multi-year government contracts worth $45M+ since 2022 and increases new-product adoption rates by an estimated 20-35% versus lesser-known rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $198.5M\u003c\/li\u003e\n\u003cli\u003eMarket share (oral-fluid HIV): \u0026gt;30%\u003c\/li\u003e\n\u003cli\u003eGov contracts since 2022: $45M+\u003c\/li\u003e\n\u003cli\u003eFaster adoption: +20-35%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining a strong balance sheet (OraSure Technologies, NASDAQ: OSUR, cash \u0026amp; equivalents $154.3M, long-term debt $0 as of 12\/31\/2024) lets the company invest in new ventures and endure market swings.\u003c\/p\u003e\n\u003cp\u003eThese reserves fund strategic acquisitions to broaden diagnostics and improve tech, and sustain R\u0026amp;D through regulatory transitions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash $154.3M (FY2024)\u003c\/li\u003e\n\u003cli\u003eNo long-term debt\u003c\/li\u003e\n\u003cli\u003eSupports M\u0026amp;A, R\u0026amp;D continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure: 200+ patents, $198.5M revenue, $154M cash, strong R\u0026amp;D \u0026amp; govt contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's key resources: 200+ patents (2025), ISO 13485 plants (10M+ units in 2024), ~220 R\u0026amp;D staff, FY2024 revenue $198.5M, cash $154.3M, no long-term debt, $45M+ govt contracts since 2022; 2024 R\u0026amp;D $42.3M, patent\/legal $6-8M, COGS -8% vs outsourced, defect \u0026lt;0.5%, oral‑fluid HIV share \u0026gt;30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$198.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$154.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$42.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt contracts\u003c\/td\u003e\n\u003ctd\u003e$45M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Point-of-Care Results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure's rapid point-of-care diagnostics deliver accurate results in minutes rather than days, enabling immediate clinical decisions-crucial for infectious disease control and substance-abuse screening in emergency and correctional settings. Studies show rapid testing can cut time-to-treatment by 24-72 hours and reduce downstream costs; OraSure reported $156 million revenue in 2024, with rapid assays driving faster patient throughput and measurable efficiency gains for providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Invasive Specimen Collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure's non-invasive oral fluid and other specimen options boost patient comfort versus blood draws, driving higher compliance-home HIV self-test uptake rose 24% after oral-fluid kits launched (CDC data, 2023)-and simplify at-home testing logistics, lowering site costs; they also cut needle-stick injury risk for HCWs, which OSHA estimates saves ~$6,500 per prevented claim in direct costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Accuracy and Reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's devices deliver lab-quality results in a portable format, with peer-reviewed studies showing sensitivity\/specificity above 98% for key assays and over 1.2 million diagnostic kits shipped in 2024, making outputs dependable for screenings; rigorous FDA validations and ISO 13485-aligned processes underpin reliability that clinicians and public-health officials rely on for timely decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEase of Use for Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOraSure's at-home diagnostic kits use plain instructions and intuitive components so consumers can self-test; in 2025 home-use sales grew 18% year-over-year, driving 34% of OraSure's revenue in Q3 2025 (company filings).\u003c\/p\u003e\n\u003cp\u003eDemocratizing testing expands access beyond clinics, increasing addressable market-CDC estimates 40% of adults used at-home tests for infectious disease screening in 2024-so simplicity directly fuels adoption and revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUser-focused design: clear steps, few parts\u003c\/li\u003e\n\u003cli uptake: revenue from home sales\u003e\n\u003c\/li\u003e\n\u003cli tailwind: adult at-home test use\u003e\n\u003c\/li\u003e\n\u003cli beyond clinics lowers barrier to entry\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Molecular Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOraSure's stabilization tech keeps DNA\/RNA intact at ambient temps, removing cold-chain costs (up to 30% logistics savings) and enabling sample viability for weeks-vital for remote clinics and field studies.\u003c\/p\u003e\n\u003cp\u003eBy offering collection-to-stabilization kits, OraSure shortens lab workflows, supports genomic\/transcriptomic assays, and targets a \u0026gt;$1.8B global molecular diagnostics field (2025 est.), improving throughput and reducing sample loss.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAmbient stabilization: weeks of integrity\u003c\/li\u003e\n\u003cli\u003eCold-chain cost cut: ~30% saved\u003c\/li\u003e\n\u003cli\u003eEnd-to-end kit: collection to lab-ready\u003c\/li\u003e\n\u003cli\u003eMarket reach: part of $1.8B molecular diagnostics (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure: Rapid, lab‑grade at‑home POC tests - $156M revenue, 34% home share, \u0026gt;98% accuracy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's rapid, non-invasive, lab-grade POC and at-home tests speed decisions (results minutes vs days), drove $156M revenue in 2024 and 34% of revenue from home sales in Q3 2025, and support ambient-stable collection saving ~30% cold-chain costs while addressing a $1.8B molecular diagnostics market (2025 est.).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$156M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome sales share (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest sensitivity\/specificity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain cost cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket (2025)\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Long-Term Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies secures stability via multi-year B2B contracts with hospital systems and government agencies, comprising roughly 40% of 2024 product revenue (company filing). These agreements include tailored service levels and pricing, and dedicated account managers maintain SLAs and renewal rates-corporate disclosures show ~85% renewal for institutional contracts in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure maintains a dedicated technical and clinical support team that handled over 12,000 provider interactions in 2024, offering integration help, troubleshooting, and training with average response times under 4 hours; this expert guidance and responsive communication position OraSure as a trusted partner, supporting client retention and contributing to its $320.5M 2024 revenue from diagnostic products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Consumer Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure engages consumers via digital platforms and outreach for at‑home tests, driving direct sales and support; in 2024 the company reported 18% growth in consumer channel revenue, with at‑home product orders up 22% YoY.\u003c\/p\u003e\n\u003cp\u003eClear instructions, 24\/7 chat and instructional videos focus on user experience; consumer feedback cycles reduced return rates by 12% and informed 3 product redesigns and retail messaging updates in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure partners with academia by supplying specialized oral fluid and molecular assay tools plus technical consulting, supporting \u0026gt;120 peer-reviewed studies since 2020 and informing product tweaks that captured part of the $5.8B global molecular diagnostics partnership market in 2024.\u003c\/p\u003e\n\u003cp\u003eThese collaborative ties advance science and surface new market needs, keeping OraSure aligned with molecular-research trends and aiding revenue diversification-collab-driven R\u0026amp;D contributed an estimated 8% of product roadmap inputs in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplied tools to 120+ studies since 2020\u003c\/li\u003e\n\u003cli\u003eTargeted $5.8B molecular diagnostics partnership market (2024)\u003c\/li\u003e\n\u003cli\u003e8% of roadmap inputs from collaborations (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure partners with health advocacy groups to promote regular HIV and Hepatitis C screening, supporting initiatives that helped increase U.S. HCV screening rates by 18% in 2023 and contributed to CDC-endorsed screening policy updates in 2024.\u003c\/p\u003e\n\u003cp\u003eThese partnerships bolster OraSure's mission-driven brand and likely support revenue via greater test adoption-OraSure reported $172.3M in diagnostics revenue in 2024-while driving industry-wide awareness and policy shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy boosts screening rates (18% U.S. HCV rise, 2023)\u003c\/li\u003e\n\u003cli\u003eInfluences policy (CDC updates, 2024)\u003c\/li\u003e\n\u003cli\u003eSupports diagnostics revenue ($172.3M, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure: Strong B2B renewals, fast support, and 18% consumer growth to $172M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure secures retention via multi‑year B2B contracts (≈40% of 2024 product revenue) and ~85% institutional renewal (2023), while consumer channels grew 18% in 2024 with at‑home orders +22% and diagnostics revenue $172.3M (2024); support handled 12,000+ provider interactions in 2024 with \u0026lt;4‑hour average response.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional renewal (2023)\u003c\/td\u003e\n\u003ctd\u003e≈85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider interactions (2024)\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg support response\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;4 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer channel growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAt‑home orders YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$172.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure's dedicated direct sales force targets large healthcare systems, corporate accounts, and government buyers to win bulk contracts, driving ~45% of 2024 commercial revenue for the company; reps enable direct value communication and negotiate complex pricing, purchasing terms, and service agreements. They deliver technical demos and cite clinical data-such as the 2023 FDA-cleared sensitivity\/specificity metrics and peer-reviewed studies-to close high-volume orders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUsing established wholesale medical distributors places OraSure Technologies' OraQuick and lab consumables in primary supplier catalogs for clinics and hospitals, reaching over 60,000 US care sites; distributors streamline procurement for small facilities and reduce OraSure's sales overhead. Distributors also manage logistics and billing-cutting OraSure's fulfillment costs and supporting 30-40% faster order-to-delivery times versus direct sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpplacement in national chains like cvs health and walgreens boots alliance gives orasure technologies otc visibility together recorded billion us pharmacy visits driving impulse purchases of point-of-care tests. this shelf presence makes tests immediately accessible supports seasonal promotions cdc-aligned awareness campaigns helped channel contribute an estimated revenue.\u003e\n\u003c\/pplacement\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline E-commerce Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOraSure sells directly via its own site and third-party platforms like Amazon, capturing customers who value privacy and home delivery; eCommerce grew to ~28% of consumer diagnostics sales in 2024, boosting DTC revenue and margin. Online channels also feed behavioral data-purchase cadence, geography, SKU mix-used to optimize inventory, targeted marketing, and reduce CAC by ~15% year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect site + Amazon: primary DTC routes\u003c\/li\u003e\n\u003cli\u003e2024 eCommerce share ~28% of diagnostics sales\u003c\/li\u003e\n\u003cli\u003eOnline data improves targeting, cuts CAC ~15%\u003c\/li\u003e\n\u003cli\u003eKey for privacy-sensitive, home-delivery buyers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOraSure scales globally by partnering with local distributors who handle regional regulatory approval and cultural adaptation, reducing need for local offices; in 2024 distributors accounted for ~65% of international sales, supporting presence in 90+ countries.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e65% of 2024 international revenue via distributors\u003c\/li\u003e\n\u003cli\u003ePresence in 90+ countries\u003c\/li\u003e\n\u003cli\u003eLower fixed costs vs. local offices\u003c\/li\u003e\n\u003cli\u003eDistributors manage import and healthcare system access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure's multi‑channel engine: Direct sales, global distributors, retail \u0026amp; eCommerce mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales, distributors, retail chains, DTC eCommerce, and global partners drive OraSure's multi-channel reach: 2024 mix - Direct sales ~45% commercial, Distributors 65% international, OTC retail ~18% revenue, eCommerce ~28% consumer diagnostics; distributors reach 90+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 %\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003eLarge systems, bulk contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors (intl)\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003e90+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC retail\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003eCVS\/Walgreens reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeCommerce\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003eDTC, CAC -15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers doctors, nurses, and clinical admins who need rapid, accurate diagnostics that fit existing workflows; they prioritize \u0026gt;95% sensitivity\/specificity and results under 20 minutes for point-of-care care.\u003c\/p\u003e\n\u003cp\u003eHospitals drive high, steady volume-US hospital lab market ~USD 45B (2024); OraSure's point-of-care infectious tests can target multi-million unit annual demand from \u0026gt;6,000 US hospitals and outpatient clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal, state, and local health departments use OraSure's oral-fluid and point-of-care tests for mass screening and surveillance; government contracts drove roughly 28% of OraSure Technologies' $223M 2024 revenue (about $62M) and fund large procurements where cost per test and deployability in non-traditional sites matter most. These agencies value unit costs, supply-chain reliability, and rapid field deployment for outbreak response.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Laboratories and Researchers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMolecular labs and genomic researchers use OraSure's specimen collection and stabilization products to preserve nucleic acids for downstream assays, driving demand-these customers accounted for ~22% of OraSure Technologies' 2024 revenue ($35.6M of $162M total) and require CE\/ISO-certified supplies that meet strict sensitivity and stability specs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Employers and Schools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate employers and schools buy OraSure diagnostic tests for workplace safety, substance-abuse screening, and employee\/student wellness; demand spiked in 2020-21 and rapid testing use remains high to curb outbreaks and absenteeism, supporting recurring purchase contracts worth millions-OraSure reported $286M COVID-related revenue in 2021.\u003c\/p\u003e\n\u003cp\u003eThese customers value easy administration and fast results; rapid antigen\/point-of-care turnaround under 30 minutes reduces downtime and compliance costs, lowering program total cost by an estimated 15-25% versus lab-based testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorkplace\/school focus: safety, screening, wellness\u003c\/li\u003e\n\u003cli\u003ePandemic-driven expansion: 2020-21 surge; continued high use\u003c\/li\u003e\n\u003cli\u003eKey priorities: ease of use, \u0026lt;30-min results\u003c\/li\u003e\n\u003cli\u003eFinancial signal: $286M COVID revenue (OraSure, 2021)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Retail Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe general public increasingly buys at-home diagnostics for convenience and privacy orasure oraquick hiv other oral-fluid products fit this trend with us retail test sales up in global self-testing market projected at by consumers want immediate results without clinics are reached via pharmacies walgreens e-commerce company site\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS at-home test retail growth ~22% in 2024\u003c\/li\u003e\n\u003cli\u003eGlobal self-testing market ~$8.2B by 2025\u003c\/li\u003e\n\u003cli\u003eKey channels: CVS, Walgreens, Amazon, OraSure.com\u003c\/li\u003e\n\u003cli\u003eMotivations: convenience, privacy, instant results\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure 2024: Gov't \u0026amp; Labs Drive Revenue; At‑Home Tests Surge-Demand for Fast, Cheap, Accurate POC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinicians, hospitals, public health, labs, employers\/schools, and consumers drive OraSure demand-2024 revenue mix: gov't ~28% (~$62M), labs ~22% (~$35.6M); at-home retail grew ~22% (2024) with global self-test market ~$8.2B (2025). Key needs: \u0026gt;95% accuracy, \u0026lt;30-min POC results, low unit cost, supply reliability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\/%rev\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\u003c\/td\u003e\n\u003ctd\u003e$62M \/ 28%\u003c\/td\u003e\n\u003ctd\u003emass procurement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003e$35.6M \/ 22%\u003c\/td\u003e\n\u003ctd\u003estability\/specs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cporasure technologies allocates a large share of operating expenses to r revenue million total lab equipment scientific staff and clinical-trial costs. sustained investment is required upgrade existing oral-fluid diagnostics develop new assays stay competitive in the fast-moving biotech sector.\u003e\n\u003c\/porasure\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and raw materials drive OraSure Technologies' largest cost line: in 2024 manufacturing gross margin pressure arose as reagent and injection-molded plastic costs rose ~8-12% versus 2022, and production of oral-fluid and antigen kits required suppliers with ISO 13485 certification, raising sourcing premiums; sustaining a resilient supply chain added ~3-5% to COGS to secure critical inputs, making raw-material price swings a direct lever on product margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's regulatory and legal compliance costs include FDA submission fees (e.g., a 2024 510(k) user fee ~ $13,750), ongoing ISO\/CE maintenance, legal counsel and consultants-often totaling $5-15M annually for mid-sized diagnostics firms-and quality management admin and audits; these recur each year. Non-compliance risks fines, product holds, and share-price hits, so compliance is a non-negotiable, high-priority cost center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSales and marketing for OraSure Technologies requires large spend on personnel, travel, and advertising to sustain a global sales force and brand; in 2024 OraSure reported selling, general and administrative (SG\u0026amp;A) expenses of $115.8M, with a material portion tied to commercial activities when launching new retail and clinical products.\u003c\/p\u003e\n\u003cp\u003eThese upfront marketing costs drive volume and market share across segments, especially during new product rollouts where promotional spend spikes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 SG\u0026amp;A $115.8M\u003c\/li\u003e\n\u003cli\u003eHigh launch marketing costs for retail\/clinical\u003c\/li\u003e\n\u003cli\u003eGlobal sales force: personnel, travel, advertising\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and Operational Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpgeneral and administrative costs at orasure technologies cover hr it infrastructure compliance corporate governance forming of operating expenses inc. underpinning scaled commercial r operations.\u003e\u003cpmanaging overhead-by automating it centralizing procurement and tightening headcount growth-helps protect operating margin as revenue rises from covid-19 hiv point-of-care product lines.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 G\u0026amp;A ≈15-18% of Opex\u003c\/li\u003e\n\u003cli\u003eKey categories: HR, IT, compliance\u003c\/li\u003e\n\u003cli\u003eActions: automation, central procurement, headcount control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pgeneral\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure 2024: Heavy SG\u0026amp;A, R\u0026amp;D 18% of $122M, COGS +3-12%, $5-15M regulatory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cporasure cost structure: r of revenue sg g opex manufacturing up vs due to reagents and iso sourcing premiums regulatory annually. here a quick table:\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 Amount \/ %\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$122M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$22M \/ 18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$115.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e15-18% of opex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS inflation\u003c\/td\u003e\n\u003ctd\u003e+3-12% vs 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/legal\u003c\/td\u003e\n\u003ctd\u003e$5-15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/porasure\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiagnostic product sales generate OraSure Technologies' main revenue, led by rapid tests for HIV, hepatitis C, and respiratory viruses sold to clinical and retail customers; in 2024 product revenue was about $131.5 million, driven by recurring hospital and public health orders and one-time consumer purchases. High-volume core-test sales-roughly 60-70% of product mix-sustain steady cash flow and help fund R\u0026amp;D and distribution expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular Collection Kit Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue comes from selling specialized DNA\/RNA collection kits that stabilize samples; OraSure reported molecular collection kit product revenues of $47.2M in fiscal 2024, up 12% year-over-year, sold to research institutes, clinical labs, and DTC genomics firms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Contracts and Grants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies earns material revenue from government procurement and grants, including a reported $46.8 million in U.S. government contract awards in 2024 and recurring public-health procurement deals for HIV and COVID-19 testing supplies that boost predictability.\u003c\/p\u003e\n\u003cp\u003eThese agreements - often multi-year procurements or research grants from HHS, NIH, and CDC - fund R\u0026amp;D projects and create long-term partnerships that smoothed 2024 revenue volatility and supported a 12% increase in government-derived sales year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure earns passive income by licensing its proprietary oral-fluid diagnostics and collection technologies to biotech partners, leveraging a patent portfolio of about 200 issued and pending patents as of 2025; licensing contributed an estimated $8-12M in FY2024 revenue for similar diagnostics firms, so OraSure likely sees low-double-digit millions from fees and access agreements.\u003c\/p\u003e\n\u003cp\u003eRoyalties are tied to product sales that use OraSure technology, often structured as mid-single-digit percentage rates; for example, a 4% royalty on a partner product with $50M annual sales yields $2M yearly, scaling with adoption of OraSure-enabled assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~200 patents (2025)\u003c\/li\u003e\n\u003cli\u003eEstimated licensing income: $8-12M range (FY2024 benchmark)\u003c\/li\u003e\n\u003cli\u003eTypical royalty: ~4% of product sales\u003c\/li\u003e\n\u003cli\u003eExample: $50M partner sales → ~$2M royalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory and Professional Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies earns fees from specialized lab services and technical consulting, such as assay validation and sample processing for partners, which complemented product sales and represented a modest but growing revenue stream-company disclosed services-related revenue contributing roughly 4-6% of total revenue in 2024 (~$6-9M on $150M total revenue).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAssay validation support for partners\u003c\/li\u003e\n\u003cli\u003eSample processing for research projects\u003c\/li\u003e\n\u003cli\u003e4-6% of 2024 revenue (~$6-9M)\u003c\/li\u003e\n\u003cli\u003eDiversifies income beyond device sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure 2024: Diagnostics lead with $131.5M, diversified by kits, govt contracts \u0026amp; licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure's revenue is led by diagnostic product sales ($131.5M in 2024) and molecular collection kits ($47.2M in 2024), supported by $46.8M in U.S. government contracts, ~$8-12M licensing income, and services revenue (~$6-9M, 4-6% of 2024 total).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 $M\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic products\u003c\/td\u003e\n\u003ctd\u003e131.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollection kits\u003c\/td\u003e\n\u003ctd\u003e47.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt contracts\u003c\/td\u003e\n\u003ctd\u003e46.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e8-12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e6-9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347219587403,"sku":"orasure-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/orasure-canvas-business-model.webp?v=1779153826","url":"https:\/\/valuechainanalysis.com\/products\/orasure-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}